As WHO staging is increasingly being used in place of CD4 measurement to identify AHD to inform the implementation of targeted interventions, it is critical to re-evaluate the accuracy of WHO staging in guiding AHD care in order to clarify the preferred approach for identifying AHD. The gene discussed is CD4; the disease is mitochondrial DNA depletion syndrome 4a.